Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Rutgers, The State University of New Jersey
NextPoint Therapeutics, Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Veana Therapeutics
DNAtrix, Inc.
Bellicum Pharmaceuticals
Roger Williams Medical Center
Envita Medical Center, Inc.